Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Last trade$3.78
Day change+$0.195 (+5.45%)
Day range$3.46 – $3.89
Volume1,602,888
Market cap$346M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$346.29M
Price / earnings
—
Price / book
4.03×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.1×
Profitability
Earnings per share
-$0.81
Return on assets
-81.16%
Return on equity
-90.66%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.92×
Quick ratio
9.92×
Cash ratio
0.86×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$65.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RZLT, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$6.58M
$6.67M
$5.95M
$9.87M
$6.67M
$4.99M
$4.74M
$4.45M
Research and development
$12.81M
$14.89M
$11.41M
$14.35M
$13.15M
$20.86M
$15.28M
$12.63M
Total operating expenses
$19.39M
$21.56M
$17.37M
$24.22M
$19.82M
$25.85M
$20.02M
$17.08M
Operating income
-$19.39M
-$21.56M
-$17.37M
-$24.22M
-$19.82M
-$25.85M
-$20.02M
-$17.08M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$18.49M
-$20.49M
-$16.17M
-$22.77M
-$18.15M
-$24.39M
-$18.91M
-$15.73M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$18.49M
-$20.49M
-$16.17M
-$22.77M
-$18.15M
-$24.39M
-$18.91M
-$15.73M
Net income attributable to common shareholders
-$18.49M
-$20.49M
-$16.17M
-$22.77M
-$18.15M
-$24.39M
-$18.91M
-$15.73M
EBITDA
-$19.38M
-$21.55M
-$17.36M
-$24.21M
-$19.81M
-$25.84M
-$20.02M
-$17.07M
Basic earnings per share
-$0.18
-$0.20
-$0.16
-$0.22
-$0.18
-$0.26
-$0.27
-$0.22
Diluted earnings per share
-$0.18
-$0.20
-$0.16
-$0.22
-$0.18
-$0.26
-$0.27
-$0.22
Recent news
Company coverage with links to the original publishers.
Rezolute, Inc., a rare disease company focused on treating hyperinsulinism, announced it will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference (May 19, 2026) and the Jefferies Global Healthcare Conference (June 2-4, 2026). The company will present oral results from its Phase 3 sunRIZE study of ersodetug in patients with congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting, including previously announced topline results and additional continuous glucose monitoring-based outcomes showing significant improvements in glycemic control.
Rezolute, Inc. (NASDAQ: RZLT) experienced a severe stock price collapse of 87.2% on December 19, 2025, following the announcement that its lead drug candidate ersodetug failed to meet primary and key secondary endpoints in the Phase 3 sunRIZE clinical trial for congenital hyperinsulinism. The drug failed to demonstrate statistically significant efficacy over placebo, prompting a securities fraud investigation by the Portnoy Law Firm.
XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.
Rezolute, Inc., a late-stage rare disease company developing ersodetug antibody therapy for hyperinsulinism-induced hypoglycemia, announced it will participate in the Citizens Life Sciences Conference on March 10-11, 2026, in Miami, FL, with management available for one-on-one investor meetings.
Rezolute, Inc. (NASDAQ: RZLT) experienced a dramatic 90% intraday stock price decline on December 11, 2025, after announcing that its Phase 3 sunRIZE trial for ersodetug failed to meet primary and secondary endpoints for treating hypoglycemia caused by hyperinsulinism. The failure contradicted the company's previous assurances about the drug's efficacy and market potential, prompting shareholder rights firm Hagens Berman to investigate potential investor fraud.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.